Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
8,55 USD | -3,82 % | +0,83 % | +73,78 % |
14/05 | Acrivon Therapeutics, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024 | CI |
29/04 | ACRIVON THERAPEUTICS, INC. : Ladenburg Thalmann permanece neutral | ZM |
Resumen de negocios
Número de empleados: 60
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 62 | 01/04/18 | |
Kristina Masson
FOU | Founder | 44 | 01/03/18 |
Director of Finance/CFO | 53 | 01/04/22 | |
Monica Phadnis
CTO | Chief Tech/Sci/R&D Officer | - | - |
Bruce Close
CMP | Compliance Officer | - | - |
Karl Hsu
CTO | Chief Tech/Sci/R&D Officer | - | 03/01 |
Chief Tech/Sci/R&D Officer | - | 03/01 | |
Eric Devroe
COO | Chief Operating Officer | 46 | 01/08/22 |
Adam Levy
IRC | Investor Relations Contact | - | 20/07/23 |
Comptroller/Controller/Auditor | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Director/Board Member | 55 | 08/02 | |
Sharon Shacham
BRD | Director/Board Member | 53 | 01/10/20 |
Chief Executive Officer | 62 | 01/04/18 | |
Michael Tomsicek
BRD | Director/Board Member | 58 | 01/10/22 |
Charles Baum
BRD | Director/Board Member | 65 | 22/06/23 |
Derek DiRocco
BRD | Director/Board Member | 43 | 01/11/21 |
Kristina Masson
FOU | Founder | 44 | 01/03/18 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 30 876 932 | 18 397 271 ( 59,58 %) | 0 | 59,58 % |
Información de la empresa
Sector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+73,78 % | 274 M | |
+41,79 % | 50,93 mil M | |
-0,56 % | 42,12 mil M | |
+49,62 % | 42,05 mil M | |
-7,20 % | 29,18 mil M | |
+12,59 % | 26,02 mil M | |
-21,51 % | 18,9 mil M | |
+6,92 % | 13,21 mil M | |
+24,91 % | 12,17 mil M | |
+29,60 % | 12,16 mil M |
- Bolsa de valores
- Acciones
- Acción ACRV
- Empresa Acrivon Therapeutics, Inc.